Drug
Ritobegron clinical trials
- studies test it
- 9
- open now
- 0
- in phase 3
- 2
- first study started
- 2003
How studies write it
Studies that test it under each name
Combined with it in one product
Studies by the year they started
6 studies that test it; most in 2004 (3)
| Year | Studies |
|---|---|
| 2003 | 2 |
| 2004 | 3 |
| 2005 | 1 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 6
- Phase 2
- 1
- Phase 3
- 2
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 9 · Other 0
Boehringer Ingelheim (6) · Kissei Pharmaceutical Co., Ltd. (3)
Often tested with
Tested in the same studies.
Ritobegron ethyl (9) · Bisoprolol (1) · Propranolol (1) · Acipimox (1)
Studies
Open first, then newest update. How each study uses ritobegron is read from its arms, and is right about nine times in ten.
Testing it · 9
- Study to Investigate the Regional Drug Absorption of KUC-7483 CL Administered Via an Enterion™ Capsule Compared to an Immediate Release Formulation in Healthy Male VolunteersCompletedPhase 1Boehringer IngelheimNCT02259920Written as KUC 7483 CL, immediate release tablet
- Safety, Tolerability and Pharmacokinetics of Single Rising Oral Doses of KUC 7483 CL Tablets in Healthy Male VolunteersCompletedPhase 1Boehringer IngelheimNCT02259764Written as KUC 7483 CL - single rising dose
- Safety, Tolerability and Pharmacokinetics of KUC 7483 Tablets in Healthy Male VolunteersCompletedPhase 1Boehringer IngelheimNCT02259907Written as KUC 7483 CL
- Study to Determine Pharmacodynamic Effects and Pharmacokinetics of KUC 7483 CL in Patients With Spinal Cord Injury and Neurogenic Detrusor OveractivityCompletedPhase 1Boehringer IngelheimNCT02259751Written as KUC 7483 CL
- Safety, Tolerability and Pharmacokinetics of KUC 7483 CL Tablets in Healthy Male VolunteersCompletedPhase 1Boehringer IngelheimNCT02259933Written as KUC 7483 CL
- In Vivo Specificity of KUC 7483 CL Co-administered With Bisoprolol, Propranolol, and Acipimox in Healthy Male SubjectsCompletedPhase 1Boehringer IngelheimNCT02256722Written as KUC 7483 CL
- A Confirmatory Study of KUC-7483 in Patients With Overactive BladderCompletedPhase 3Kissei Pharmaceutical Co., Ltd.NCT01004315Written as KUC-7483
- Long-term Safety and Efficacy of KUC-7483 in Patients With Overactive BladderWithdrawnPhase 3Kissei Pharmaceutical Co., Ltd.NCT01003405Written as KUC-7483
- A Phase II Study of KUC-7483 in Patients With Overactive BladderCompletedPhase 2Kissei Pharmaceutical Co., Ltd.NCT00742833Written as KUC-7483
Codes
What other systems call ritobegron · ClinicalTrials.gg INT006177
- MeSH (NLM) C576374ritobegronConfirmed NLM, Wikidata
- UNII (FDA) LD86RKR53MRITOBEGRONConfirmed FDA, NLM, Wikidata
- Wikidata Q27282934ritobegronConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C87677RitobegronOne source FDA
- DrugBank DB12080One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C576374 | ritobegron | Confirmed NLM, Wikidata |
| UNII (FDA) | LD86RKR53M | RITOBEGRON | Confirmed FDA, NLM, Wikidata |
| Wikidata | Q27282934 | ritobegron | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C87677 | Ritobegron | One source FDA |
| DrugBank | DB12080 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.